RenovoRx, Inc. (RNXT)
Nasdaq · Healthcare · Biotechnology
$1.47−6.96%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $66.3M
- 52-week range
- $0.701 – $2.59
- 52-week change
- +17.91%
- EPS (trailing)
- −$0.31
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $1.1M (+2511.63%)
- Net income
- −$11.2M
- Operating margin
- −1114.0%
- Diluted EPS
- −$0.32
- Free cash flow
- −$11.0M
From the company’s annual report on SEC EDGAR.
About RenovoRx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Headquarters: Mountain View, United States · 17 employees · renovorx.com